1. Home
  2. INVE vs ASMB Comparison

INVE vs ASMB Comparison

Compare INVE & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Identiv Inc.

INVE

Identiv Inc.

HOLD

Current Price

$3.42

Market Cap

80.1M

Sector

Technology

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$33.29

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INVE
ASMB
Founded
1990
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.1M
553.6M
IPO Year
1997
2010

Fundamental Metrics

Financial Performance
Metric
INVE
ASMB
Price
$3.42
$33.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$5.50
$43.40
AVG Volume (30 Days)
37.6K
140.2K
Earning Date
11-10-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,015,000.00
$37,191,000.00
Revenue This Year
N/A
$33.33
Revenue Next Year
$11.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.30
52 Week Low
$2.86
$7.75
52 Week High
$4.07
$39.71

Technical Indicators

Market Signals
Indicator
INVE
ASMB
Relative Strength Index (RSI) 45.52 46.76
Support Level $3.40 $31.51
Resistance Level $3.70 $38.99
Average True Range (ATR) 0.15 2.15
MACD -0.00 -0.32
Stochastic Oscillator 23.84 25.13

Price Performance

Historical Comparison
INVE
ASMB

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: